Spots Global Cancer Trial Database for Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors
Official Title: A Phase I Dose Escalation Study of JX-594 (Thymidine Kinase-deleted Vaccinia Virus Plus GM-CSF) Administered by Intravenous Infusion in Patients With Refractory Solid Tumors
Study ID: NCT00625456
Interventions
Study Description
Brief Summary: This is a Phase I, open-label, dose-escalation trial in patients with advanced/metastatic solid tumors refractory to standard therapy; tumors may include malignant melanoma, non-small cell lung cancer, renal cell carcinoma, and squamous cell carcinoma of the head and neck. These tumor types were selected because evidence of biological activity was observed in these tumor types in a Phase I study of JX-594 (Pexa-Vec) administered by intratumoral injection in patients with metastatic disease to the liver. Patients will receive treatment at one of five dose levels in a sequential dose-escalating design.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Billings Clinic, Billings, Montana, United States
University of Pennsylvania, Philadelphia, Pennsylvania, United States
Cancer Centers of the Carolinas, Greenville, South Carolina, United States
Ottawa Health Research Institute, Ottawa, Ontario, Canada
Contact Details
Name: David Kirn, MD
Affiliation: Jennerex Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
